Skip to main content
Premium Trial:

Request an Annual Quote


Sanofi-Aventis wants to make its interest in Genzyme official, reports the Wall Street Journal's Health Blog. Last week, the Journal reported that "the two sides have begun sounding out each other's interest in a deal before entering into formal talks and a completed transaction is far away." This week, the New York Times says that "Sanofi-Aventis is likely to make an unsolicited offer of up to $70 a share for Genzyme," which would then total $18.6 billion and "could become one of the year's biggest deals."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.